Your browser doesn't support javascript.
loading
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali, Siraj M; Sanford, Eric M; Klempner, Samuel J; Rubinson, Douglas A; Wang, Kai; Palma, Norma A; Chmielecki, Juliann; Yelensky, Roman; Palmer, Gary A; Morosini, Deborah; Lipson, Doron; Catenacci, Daniel V; Braiteh, Fadi; Erlich, Rachel; Stephens, Philip J; Ross, Jeffrey S; Ou, Sai-Hong Ignatius; Miller, Vincent A.
Afiliação
  • Ali SM; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Sanford EM; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Klempner SJ; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Rubinson DA; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Wang K; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Palma NA; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Chmielecki J; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Yelensky R; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Palmer GA; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Morosini D; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Lipson D; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Catenacci DV; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Braiteh F; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Erlich R; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Stephens PJ; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Ross JS; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Ou SH; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
  • Miller VA; Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University
Oncologist ; 20(5): 499-507, 2015 May.
Article em En | MEDLINE | ID: mdl-25882375
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Carcinoma / Instabilidade Genômica / Proteínas de Neoplasias Tipo de estudo: Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Carcinoma / Instabilidade Genômica / Proteínas de Neoplasias Tipo de estudo: Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de publicação: Reino Unido